https://doi.org/10.4081/itjm.2023.1627
Association of TNF-α, IFN-γ, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection
Published: 18 July 2023
Abstract Views: 652
PDF: 299
HTML: 42
HTML: 42
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Cytokines have a crucial part in the pathogenesis, persistence of infection, and prognosis of hepatitis B virus (HBV) infection as HBV does not cause direct liver destruction; rather, disease-related complications and prognosis are more associated with immune system action, specifically cytokines such as TNF-α, IFN-γ, IL-6, IL-10, and other cytokines. This study sought to link TNF-, IFN-, IL-6, and IL-10 to various clinical manifestations of HBV infection. Ninety sera were taken from HBV-infected patients, 30 (33.3%) of whom had liver cirrhosis, 30 (33.3%) were HBV carriers, 19 (21.2%) were acute HBV patients, and 11 (12.2%) were recently HBV infected. ELISA was used to determine the serum levels of TNF-α, IFN-γ, IL-6, and IL-10. HBV-infected patients with liver cirrhosis had considerably higher mean serum levels of IFN-γ (P=0.005) and IL-10 (P=0.003), but TNF-α and IL-6 were significantly higher in recent HBV-infected patients (P values 0.034 and 0.004, respectively). There were substantial changes in mean serum levels of TNF-α, IFN-γ, IL-6, and IL-10 at different phases of HBV infection, implying a role for cytokines in HBV etiology, chronicity, and consequences.
Wong DJ, Locarnini SA, Thompson AJV. Hepatitis B virus. In Richman DD, Whitley RJ, Hayden FG. Clinical virology, 4th ed. ASM Press. Washington DC, USA. 2017;713-70.
DOI: https://doi.org/10.1128/9781555819439.ch32
Sheron N, Lau J, Daniels H, et al. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol 1991;12:241-5.
DOI: https://doi.org/10.1016/0168-8278(91)90945-8
Cagri BA, Buke M, Altuglu IE, et al. Tumor Necrosis Factor Alpha and Interleukin 6 Productions in Response to Platelet-Activating Factor in Chronic Hepatitis B Virus Infection. J Med Princ Pract 2004;13:273-6.
DOI: https://doi.org/10.1159/000079526
Bilgic Y, Seckin Y, Cagin YF, et al. Does the tumor necrosis factor a predictor factor in patients with chronic hepatitis B and C. J Biomed Res 2017;28:1683-7.
Lau JY, Bain VG, Naoumov NV, et al. Effect of interferon-gamma on hepatitis B viral antigen expression in primary hepatocyte culture. J Hepatol 1991;14:975-9.
DOI: https://doi.org/10.1002/hep.1840140604
Xia C, Liu Y, Chen Z, Zheng M. Involvement of Interleukin-6 in Hepatitis B Viral Infection. Cell Physiol Biochem 2015;37:677-86.
DOI: https://doi.org/10.1159/000430386
Tang S, Liu Z, Zhang Y, et al. Rather than rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese han population. Dis Markers 2013;35:799-805.
DOI: https://doi.org/10.1155/2013/508023
Luo MX, Wong SH, Chan MT, et al. Autophagy mediates hbx-induced nuclear factor-kappab activation and release of il-6, il-8, and cxcl2 in hepatocytes. J Cell Physiol 2015;230:2382-2389.
DOI: https://doi.org/10.1002/jcp.24967
Chau G, Wu C, Lui W, et al. Serum interleukin IL-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552-8.
DOI: https://doi.org/10.1097/00000658-200004000-00015
Fioravanti J, Lucia PD, Magini D, et al. Effector CD8 + T cell-derived interleukin-10 enhances acute liver immunopathology. J Hepatol 2017;67:543-8.
DOI: https://doi.org/10.1016/j.jhep.2017.04.020
Weng HL, Cai MW, Wang BE, et al. Clinical study of anti-hepatic fibrosis effect of INF-gamma in patients with chronic hepatitis B. Chin Med J 2003;83:943-47.
Weng HL, Wang BE, Jia JD, et al. Effect of interferongamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. J Clin Gastroenterol Hepatol 2005;3:819-28.
DOI: https://doi.org/10.1016/S1542-3565(05)00404-0
Wu YJ, Cai MW, Li Q, et al. Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection. Hepatobiliary Pancreat Dis Int J 2011;10:151-7.
DOI: https://doi.org/10.1016/S1499-3872(11)60024-6
Matskevich AA, Cordelier P, Strayer DS. Conditional expression of INF-alpha and INF-gamma activated by HBV as genetic therapy for hepatitis B. J Interferon Cytokine Res 2003;23:709-21.
DOI: https://doi.org/10.1089/107999003772084824
Paul S, Tabassum S, Islam MN. Interferon-gamma (INFgamma) response to different hepatitis B virus antigens in hepatitis B infection. J Bangladesh Med Rese Counc Bull 2004;30:72-7.
Quancheng K, Duolu Li, Zujiang Y. Specific expression of human interferon-gamma controls hepatitis B virus replication in vitro in secreting hepatitis B surface antigens hepatocytes. J Virol Methods 2012;180:84-90.
DOI: https://doi.org/10.1016/j.jviromet.2011.12.016
Wieland SF, Vega RG, Müller R, et al. Searching for interferon- induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 200;7:1227-36.
DOI: https://doi.org/10.1128/JVI.77.2.1227-1236.2003
Toyonaga T, Hinot O, Sugai S, et al. Chronic active hepatitis in transgenic mice expressing interferon-y in the liver. Proc Natl Acad Sci USA 1994;91:614-8.
DOI: https://doi.org/10.1073/pnas.91.2.614
Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. J Clin Transl Immunol 2016;5:e115.
DOI: https://doi.org/10.1038/cti.2016.68
Nobili L, Albani L, Gabrielli A, Moroncini G. Reactivation of Hepatitis B Virus Infection Associated with Anti-Tumor Necrosis Factor-α Therapy. J Antivir Antiretrovir 2014;6:92-101.
DOI: https://doi.org/10.4172/jaa.10000104
Biermer M, Puro R, Schneider RJ. Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-β. J Virol 2003;77:4033-42.
DOI: https://doi.org/10.1128/JVI.77.7.4033-4042.2003
Tzeng HT, Tsai HF, Chyuan IT, et al. Tumor Necrosis Factor-Alpha Induced by Hepatitis B Virus Core Mediating the Immune Response for Hepatitis B Viral Clearance in Mice Model. PLoS ONE 2014;9:e103008.
DOI: https://doi.org/10.1371/journal.pone.0103008
Bouezzedine F, Fardel O, Gripon P. Interleukin 6 inhibits HBV entry through NTCP down-regulation. Virol J 2015;481:34-42.
DOI: https://doi.org/10.1016/j.virol.2015.02.026
Palumbo GA, Scisciani C, Pediconi N, et al. IL-6 Inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLOS ONE 2015;10:e0142599.
DOI: https://doi.org/10.1371/journal.pone.0142599
Galun E, Nahor O, Eid A, et al. Human Interleukin-6 Facilitates Hepatitis B Virus Infection in Vitro and in Vivo. J Virol 2000;270:299-309.
DOI: https://doi.org/10.1006/viro.2000.0210
Lan T, Chang L, Wu L, Yuan Y. IL-6 Plays a Crucial Role in HBV Infection. J Clin Transl Hepatol 2015;3:271-6.
DOI: https://doi.org/10.14218/JCTH.2015.00024
Zhang F, Yao S, Zhang M, et al. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis 2011;15:e267-e271.
DOI: https://doi.org/10.1016/j.ijid.2010.12.008
Tülek N, Saglam Sk, Saglam M, et al. Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection. J Hepatogastroenterol 2000;47:828-31.
Wang K, Wu Z, Ye Y, et al. Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. J Hepat Mon 2014;14:e19370.
DOI: https://doi.org/10.5812/hepatmon.19370
Nabioullin R, Sone S, Mizuno K, et al. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol 1994;55:437-42.
DOI: https://doi.org/10.1002/jlb.55.4.437
Hyodo N, Nakamura I, Imawari M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. J Clin Exp Immunol 2004;135:462-6.
DOI: https://doi.org/10.1111/j.1365-2249.2003.02376.x
Ӧzgüler M, Akbulut HH, Akbulut A. Evaluation of Interleukin-10 Levels in Patients Diagnosed with Chronic Hepatitis. West Indian Med J 2015;64:71-5.
DOI: https://doi.org/10.7727/wimj.2014.154
How to Cite
Abdelkareem Abakar, M. A., Hussein Ali, A. A., Ahmed Elhassan, E. D., Hamuda Altaher, E. A., Abdalbasit Musa, N. H., Kafi, S. K., Fawzi Osman, A. E., & Waggiallah, H. A. (2023). Association of TNF-α, IFN-γ, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection. Italian Journal of Medicine, 17(2). https://doi.org/10.4081/itjm.2023.1627
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
